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compared with that in a control group (23.0% and 32.3% compared with 11.4%, P<.01). There was no
correlation between estimated blood loss or ΔHb and severity of intrahepatic cholestasis of pregnancy.
CONCLUSIONS In our cohort of women with intrahepatic cholestasis of pregnancy who are treated with
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PostpartumBlood Loss inWomen Treated for
Intrahepatic Cholestasis of Pregnancy
Romana Furrer, MD, Katharina Winter, Leonhard Schäffer, MD, Roland Zimmermann, MD,
Tilo Burkhardt, MD, and Christian Haslinger, MD
OBJECTIVE: To evaluate postpartum blood loss in
women with treated intrahepatic cholestasis of preg-
nancy.
METHODS: In a retrospective case–control study, 15,083
deliveries including 348 women with intrahepatic cho-
lestasis of pregnancy (2.3%) were analyzed from 2004 to
2014. To adjust for differences in baseline characteristics,
a propensity analysis was performed and women in the
control group were matched to the women in the in-
trahepatic cholestasis of pregnancy group in a 5:1 ratio.
Blood loss was analyzed by estimated blood loss and D
hemoglobin (Hb, difference between prepartum and
postpartum Hb). A subgroup analysis regarding severity
of intrahepatic cholestasis of pregnancy based on maxi-
mum bile acid level (mild [less than 40 micromoles/L],
moderate [40–99 micromoles/L], and severe intrahepatic
cholestasis of pregnancy [100 micromoles/L or greater])
was performed. Differences in estimated blood loss,
DHb, and meconium staining between subgroups were
analyzed. A Spearman rank correlation was performed to
evaluate the association of bile acid levels and blood loss
within subgroups.
RESULTS: Estimated blood loss (median 400 [300–600]
mL compared with 400 [300–600] mL, P5.22), DHb (14.0
[5.0–22.0] compared with 12.0 [4.0–21.0] g/L, P5.09),
meconium staining (14.5% compared with 11.4%,
P5.12), and number of stillbirths after 26 weeks of
gestation (0.6% compared with 1.8%, P5.10) were not
significantly different in the study compared with the
control group. In moderate and severe intrahepatic cho-
lestasis of pregnancy, meconium staining was observed
significantly more often compared with that in a control
group (23.0% and 32.3% compared with 11.4%, P,.01).
There was no correlation between estimated blood
loss or DHb and severity of intrahepatic cholestasis of
pregnancy.
CONCLUSIONS: In our cohort of women with intra-
hepatic cholestasis of pregnancy who are treated with
ursodeoxycholic acid and have planned delivery (induc-
tion of labor or planned cesarean delivery) at 38 weeks of
gestation, no differences in postpartum blood loss were
seen.
(Obstet Gynecol 2016;0:1–5)
DOI: 10.1097/AOG.0000000000001693
Intrahepatic cholestasis of pregnancy is the mostcommon liver condition uniquely manifested dur-
ing pregnancy.1 The diagnosis of intrahepatic chole-
stasis of pregnancy is made by exclusion of other
causes as well as the presence of clinical features in
association with elevated bile acid levels.2 Intrahe-
patic cholestasis of pregnancy has been associated
with a variety of adverse fetal outcomes, including
preterm delivery, meconium staining of the amniotic
fluid, and intrauterine fetal demise.3–5 Studies have
shown a significant correlation of the level of serum
bile acids with the incidence of adverse events.5,6
Apart from the occasionally massive distress
caused by the generalized pruritus, intrahepatic cho-
lestasis of pregnancy rarely poses a severe risk to
maternal health; however, a rare and serious threat for
the mother can occur in the presence of steatorrhea
from fat malabsorption and subsequently reduced
levels of vitamin K-dependent coagulation factors II,
VII, IX, or X.7 An increased risk for intrapartum
hemorrhage induced by intrahepatic cholestasis of
pregnancy has been suggested,8 especially in women
who did not receive vitamin K in pregnancy.9,10
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However, no difference in coagulation parameters
(partial thromboplastin time, platelet count) in women
with intrahepatic cholestasis of pregnancy was re-
ported.11 Because the association of postpartum hem-
orrhage with intrahepatic cholestasis of pregnancy
was not proven in a large study population, the objec-
tive of our study was to analyze postpartum blood loss
in women with intrahepatic cholestasis of pregnancy
and to evaluate the association of bile acid levels
(severity of intrahepatic cholestasis of pregnancy) with
postpartum blood loss.
MATERIALS AND METHODS
This is a retrospective, case–control, single-center
study. Data were collected from our electronic data-
base, Perinat, which contains all the patients’ diagno-
ses and prospectively collected clinical data on the
course of the pregnancy, delivery as well as maternal
and neonatal outcome. Data were recorded prospec-
tively immediately after the delivery by the midwife
and the attending physician. The study has ethical
approval according to the ethics review board of Zur-
ich (reference number KEK-ZH-Nr. 2015-0449).
All deliveries after 22 weeks of gestation at our
University Hospital from November 2004 to Novem-
ber 2014 were included. Exclusion criteria for both
women in the case group and those in the control
group were known risk factors for postpartum bleed-
ing such as placentation pathology, known coagula-
tion disorders, and liver dysfunction. The study
examined 15,083 women including 348 women with
intrahepatic cholestasis of pregnancy (2.3%). All
women with intrahepatic cholestasis of pregnancy
were treated with 900 mg ursodeoxycholic acid
administered twice daily, which is the standard dosage
at our institution, and were planned for induction
of labor or planned cesarean delivery at 38 weeks of
gestation. Women with intrahepatic cholestasis of
pregnancy usually did not receive increased antenatal
surveillance such as a nonstress test or biophysical
profile before 38 weeks of gestation. The therapy
regimen for intrahepatic cholestasis of pregnancy did
not change throughout the study period.
Data on the following obstetric parameters were
collected: cholestasis of pregnancy, bile acid level,
number of fetuses, parity, induction of labor, maternal
age at delivery, body mass index (BMI, calculated as
weight (kg)/[height (m)]2), estimated blood loss, blood
transfusion, mode of delivery (spontaneous deliveries,
assisted vaginal deliveries, type of cesarean delivery
[elective, unplanned, repeat], urgent cesarean deliv-
ery), hemoglobin (Hb) level before and after delivery,
and gestational age at birth. The obtained neonatal
information included admission to the neonatal inten-
sive care unit, neonatal birth weight, arterial umbilical
cord pH, 5-minute and 10-minute Apgar scores,
meconium staining of the amniotic fluid, and peripar-
tum demise.
To adjust for differences in baseline character-
istics, a propensity analysis was performed and
women in the control group were matched to the
women in the intrahepatic cholestasis of pregnancy
case group in a 5:1 ratio (1,725 compared with 345).
Propensity score matching was performed on a logit
scale with a caliper of 0.2. During the matching
process, three women with intrahepatic cholestasis
of pregnancy revealed no propensity scores as a result
of missing data and hence were excluded from further
analysis. The following criteria were used for match-
ing: gestational age, maternal age, maternal BMI,
multiparity, multiple gestation, induction of labor, and
mode of delivery (including 21 possibilities of spon-
taneous vaginal delivery, vaginal operative delivery,
elective and unplanned cesarean delivery, and repeat
cesarean delivery according to delivery mode and
parity). Baseline comparison between women with
and without intrahepatic cholestasis of pregnancy was
calculated. Differences between these two groups
were analyzed with Fisher exact test for categorical
variables (multiple gestation, induction of labor,
parity) and with the two-tailed t test for numeric var-
iables (BMI, maternal age, gestational age).
In a second step, the outcome of these two groups
was compared pairwise with the Mann-Whitney U test
for continuous variables and the Fisher exact test for
categorical variables. Blood loss was analyzed by esti-
mated blood loss and DHb (difference between prepar-
tum and postpartum Hb). In our institution,
determination of Hb level is performed routinely pre-
partum as well as postpartum for all parturient women.
Finally, three subgroups were defined in women
with intrahepatic cholestasis of pregnancy regarding
the severity of intrahepatic cholestasis of pregnancy
using maximum level of bile acids (mild [less than 40
micromoles/L], moderate [40–99 micromoles/L], and
severe intrahepatic cholestasis of pregnancy [100 mi-
cromoles/L or greater]). Differences in estimated
blood loss, DHb, and meconium staining of the amni-
otic fluid between subgroups were analyzed with x2
test and Kruskal-Wallis test. A Spearman rank corre-
lation was performed to evaluate the association of
bile acid level and blood loss within subgroups.
In case of missing values, the respective patient
was excluded from the related analysis. Regarding the
analysis of blood loss, only four patients with intra-
hepatic cholestasis of pregnancy had to be excluded as
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a result of unreliable estimated blood loss. DHb was
obtained in all patients with intrahepatic cholestasis of
pregnancy. In the control group, 15 patients were
excluded from analysis for differences in DHb as
a result of incomplete data.
All statistical analyses were performed using
IBM SPSS Statistics 22.0 and the R for propensity
score matching. P,.05 was considered statistically
significant.
RESULTS
After matching, all baseline characteristics were com-
parable between study and control groups (Table 1).
Neonatal and maternal outcome is shown in Table 2.
The estimated blood loss was not significantly higher
in the intrahepatic cholestasis of pregnancy group.
There was no difference in the Hb levels prepartum
and postpartum between groups. The number of
blood transfusions did not differ between the two
groups. Meconium staining of amniotic fluid was not
significantly more frequent in women with cholestasis.
The number of stillbirths was not significantly differ-
ent in the nonintrahepatic cholestasis of pregnancy
group in stillbirths after 26 weeks of gestation. In
women with intrahepatic cholestasis of pregnancy,
two cases of stillbirth after 26 weeks of gestation were
observed. One patient was admitted to the hospital
with preterm prelabor rupture of membranes at 33
weeks of gestation and bile acid level of 96 micro-
moles/L. The second case was associated with a gen-
eralized nonimmunologic fetal hydrops at 29 weeks of
gestation.
Neonatal outcome parameters were also compa-
rable between the two groups: umbilical arterial pH,
the 5-minute Apgar score as well as the rate of
admission to the neonatal care unit were similar in
both groups. Ten-minute Apgar score was signifi-
cantly higher in the intrahepatic cholestasis of preg-
nancy group, although clinically not relevant.
Among the 345 women with intrahepatic chole-
stasis of pregnancy, there were 240 cases of mild, 74 of
moderate, and 31 of severe cholestasis. In the sub-
group analysis, there was no significant association
between bile acid levels and estimated blood loss or
DHb (Table 3).
Meconium staining of the amniotic fluid corre-
lated with the severity of intrahepatic cholestasis of
pregnancy. In moderate and severe intrahepatic
cholestasis of pregnancy, meconium staining was
observed significantly more often compared with
women in the control group.
DISCUSSION
Our results do not support the theory of increased
postpartum blood loss resulting from intrahepatic
cholestasis of pregnancy in our cohort of actively
managed women. Estimated blood loss and DHb were
not significantly higher in the intrahepatic cholestasis
of pregnancy group.
Blood loss of more than 500 mL was found in one
study in 17% of 70 women with intrahepatic chole-
stasis of pregnancy9 and in another study in 20% of 50
women with intrahepatic cholestasis of pregnancy.8
On the contrary, DeLeon11 found blood loss of more
than 500 mL in women with intrahepatic cholestasis
Table 1. Baseline Characteristics After Matching
Baseline Characteristics
Intrahepatic Cholestasis
of Pregnancy (n5345)
Women in the
Control Group (n51,725) P
Multiple gestation 79 (22.9) 393 (22.8) .94*
Induction of labor 140 (40.6) 693 (40.2) .90*
Planned cesarean delivery 95 (27.5) 471 (27.7) .98*
Unplanned cesarean delivery 80 (23.2) 435 (25.2) .47*
Spontaneous vaginal deliveries 147 (42.6) 723 (41.9) .86*
Operative vaginal deliveries 23 (6.7) 96 (5.6) .50*
Multiparity 143 (41.4) 697 (40.4) .72*
BMI (kg/m2) 22.9616.8 22.964.3 .82†
Age (y) 32.065.7 32.165.5 .63†
Gestational age (d) 262.6616.8 262.1625.7 .75†
BMI, body mass index.
Data are n (%) or mean6standard deviation unless otherwise specified.
Matching criteria: gestational age, maternal age, maternal BMI, multiparity, multiple gestation, induction of labor, and mode of delivery
(including 21 possibilities of spontaneous vaginal delivery, vaginal operative delivery, elective and unplanned cesarean delivery, and
repeat cesarean delivery according to delivery mode and parity).
* Fisher exact test.
† Two-tailed t test.
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of pregnancy in only 2.4% after vaginal delivery and
6.3% after cesarean delivery. Brouwers et al6 defined
postpartum hemorrhage as a blood loss of more than
1,000 mL, which was found in 7.4% of 215 patients.
However, in these studies, no comparison with a con-
trol group was performed. Furthermore, analysis of
blood loss was done by estimation of blood loss,
whereas our study also calculated DHb as an objective
parameter.
The role of vitamin K in women with intrahepatic
cholestasis of pregnancy is still unclear. In a small
study of 70 women including 11 women without
vitamin K supplementation, Kenyon et al9 found that
postpartum bleeding was increased. Only one
national guideline deals with intrahepatic cholestasis
of pregnancy and a possible benefit from vitamin K
supplementation in the presence of malabsorption.10
Contrary to the recommendation of the Royal
College of Obstetricians and Gynaecologists, we did
not routinely measure prothrombin time in women
with intrahepatic cholestasis of pregnancy throughout
pregnancy and vitamin K was not administered before
delivery. In accordance with the results of our study,
the role of vitamin K in postpartum bleeding in
women with intrahepatic cholestasis of pregnancy
might be questioned.
In our cohort of 345 women with intrahepatic
cholestasis of pregnancy who followed a standard ther-
apy regimen toward active management for intrahepatic
cholestasis of pregnancy, first by treating every patient
with 900 mg ursodeoxycholic acid twice a day and
second by planned delivery after 38 completed weeks of
gestation, no increased incidence of adverse fetomaternal
outcome was observed apart from increased meconium
staining in the subgroup of women with severe intra-
hepatic cholestasis of pregnancy. Induction of labor was
Table 2. Neonatal and Maternal Outcomes in Women With Intrahepatic Cholestasis of Pregnancy and
Women in the Control Group
Outcome
Intrahepatic Cholestasis
of Pregnancy (n5345)
Women in the
Control Group (n51,725) P
Maternal
EBL (mL) 400 (300–600) 400 (300–600) .22*
DHb (g/L) 14.0 (5–22) 12.0 (4–21) .09*
Blood transfusion 3 (0.9) 10 (0.6) .47†
Neonatal
Birth weight (g) 3,060 (2,595–3,465) 3,030 (2,420–3,490) .37*
Meconium staining 50 (14.5) 197 (11.4) .12†
Stillbirth 3 (0.9) 62 (3.6) ,.01†
Stillbirth at greater than 26 wk of gestation 2 (0.6) 31 (1.8) .10†
Umbilical arterial pH 7.2860.07 7.2960.19 ,.01*
5-min Apgar score 9 (9–9) 9 (9–9) .37*
10-min Apgar score 9 (9–10) 9 (9–9) ,.01*
Admission to neonatal care unit 55 (15.9) 290 (16.8) .75†
EBL, estimated blood loss; DHb, difference between prepartum and postpartum hemoglobin.
Data are median (25th percentile—75th percentile), n (%), or mean6standard deviation unless otherwise specified.
* Mann-Whitney U test.
† Fisher exact test.
Table 3. Incidence of Meconium, Delta Hemoglobin, and Estimated Blood Loss in the Subgroups of
Intrahepatic Cholestasis of Pregnancy
Outcome
Women in the Control
Group (n51,725)
Mild
(n5240)
Moderate
(n574)
Severe
(n531) P
Meconium staining 11.4 9.6 23 32.3 ,.01*
DHb (g/L) 12 (12–21) 13.5 (13.5–22) 13.5 (13.5–22) 17 (17–24) .26†
EBL (mL) 400 (300–600) 400 (300–600) 500 (300–625) 450 (300–500) .37†
DHb, difference between prepartum and postpartum hemoglobin; EBL, estimated blood loss.
Data are % or median (25th percentile—75th percentile) unless otherwise specified.
Mild intrahepatic cholestasis of pregnancy, less than 40 micromoles/L bile acid; moderate intrahepatic cholestasis of pregnancy, 40–99
micromoles/L bile acid; severe intrahepatic cholestasis of pregnancy, 100 micromoles/L or greater bile acid.
* x2 test.
† Kruskal-Wallis test.
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performed in 40% of patients with intrahepatic cholesta-
sis of pregnancy. We used a relatively high dose of
ursodeoxycholic acid (1,800 mg daily) compared with
most other studies.12,13 This treatment protocol was
based on an interdisciplinary consensus, the reasonable
pharmacologic safety of ursodeoxycholic acid, and re-
ported dosages of up to 2 g.14
In our cohort, there were only two stillbirths in
women with intrahepatic cholestasis of pregnancy
after 26 weeks of gestation. This small number
prevents meaningful comparison with our control
group. Neonatal outcome was not the focus of our
study, but these results, in light of data suggesting
a higher stillbirth rate in women with intrahepatic
cholestasis of pregnancy, encourage us to continue
our current active management of patients with intra-
hepatic cholestasis of pregnancy.
The strength of our study is that we analyzed
blood loss with two different methods, first by
calculation of DHb and second by measurement of
blood loss during delivery. Blood loss is measured
in all vaginal deliveries at our institution with a quan-
titative method. In case of increased bleeding, which
is verified by regularly weighing the pads, a plastic
bag with a quantitative scale is installed under the
woman’s pelvis. It is known that without a quantitative
measurement method, blood loss is often underesti-
mated.15,16 The calculation of DHb by measurement
before and after delivery poses an objective variable
to examine blood loss during birth. Because it is rou-
tine in our institution to determine Hb levels in all
parturient women before as well as after delivery, no
woman with intrahepatic cholestasis of pregnancy and
only 15 women in the control group were excluded
from analysis as a result of missing DHb. Moreover,
matching was possible for all relevant criteria (multi-
ple gestation, induction of labor, parity, maternal age,
gestational age, BMI) in our study population with
15,083 women. Without matching, no appropriate
comparison is possible, because the frequency of mul-
tiple gestation and induction of labor is higher as
a result of the pathophysiology and management of
intrahepatic cholestasis of pregnancy. This statistical
approach is an important advantage of our study.
Apart from possible limitations of a single-center
study, its positive aspect was that a uniform therapy
management was applied over the entire study period.
In conclusion, according to our data, women with
intrahepatic cholestasis of pregnancy do not show
increased postpartum blood loss or significant adverse
outcomes in pregnancies with an active management
strategy including 23900 mg ursodeoxycholic acid
daily and planned delivery by induction of labor or
planned cesarean delivery at 38 weeks of gestation.
Administration of vitamin K does not appear to be
necessary.
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